Clinical Trial Search

Primary: Number of Subjects With Dose Limiting Toxicities — 0 Participants

Primary: Clinical Response Rate Following Induction Chemotherapy — 10; 20; 9 Participants

Primary: Evaluate the Tumor Shrinkage (%) to Measure the Deep Response Rate (DRR) — 25; 26; 0 Participants

Primary: 1-year Local Control — NA; NA months

Primary: Toxicities Associated With Combined Radiotherapy and Erlotinib Treatments. — 15; 14; 12; 13 number of adverse events

Primary: Number of Patients With Solitary Elective Volume Recurrence — 0 Participants

Primary: Percentage of Patients With Local-regional Control Rate — 100 percentage

Primary: Median Change in Quality of Life (QOL) From Baseline to 12 Months Post Treatment — -4.2; 0; 6.3; 10.7 score on a scale

Primary: Pathologic Complete Response Rate — 45.5 percentage of complete response

Primary: Number of Participants With Pathologic Complete Response (pCR) as Assessed by Independent Central Pathology Review — 40 Participants

Primary: Percentage of Participants With Local Regional Control — 91.1 percentage of subjects

Primary: 20 Week Progression Free Survival Rate — 0.90 proportion of participants

Primary: Locoregional Recurrence Rates in Cohorts 1 and 2 — 2; 2 Participants

Primary: Adverse Events Will be Assessed and Graded Using CTCAE 4.0. Occurrences With Max Grade and Percentage/Number of Participants Affected by AEs Will be Provided. — 57…

Primary: Overall Response Rate — 11; 1; 10 Participants — p=0.0005

Primary: Number of Participants Who Experience a Pathologic Complete Response (pCR) — 0; 0 Participants

Primary: Percentage of Participants With Pathologic Complete Response (pCR) as Determined by Local Pathologic Review — 16.7; 50.0 percentage of participants

Primary: Objective Response Rate — 37.5; 5.9; 0; 16.7 percentage of patients

Primary: Event-free Survival Rate at 1 Year — 0.79 proportion of patients

Primary: Number of Participants With Progression-Free Survival (PFS) — 27 Participants

Primary: Recurrence-Free Survival (RFS) as Assessed by the Investigator and Confirmed by Biopsy — 53.3; 53.7 Months — p=0.07243

Primary: Progression Free Survival — 7.9 months

Primary: 1-year Local Progression-free Survival (PFS) — 60 percentage of participants

Primary: Overall Survival (OS) Status in the PD-L1 TC/IC High Subgroup - Durvalumab Versus Standard of Care (SOC) — 162; 84; 77; 1 Participants — p=0.787

Primary: Arm 1 and Arm 2: Clinical Complete Response Rate as Measured by Clinical Exam at the Primary Tumor Site — 28; 8 Participants

Primary: 2-year Progression-free Survival Rate — 47 proportion of participants

Primary: Disease-free Survival — 57.3; 65.9 percentage of participants — p=0.05

Primary: Progression-free Survival (PFS) — 65 percentage of patients

Primary: One-year Progression-free Survival (PFS) — 97.50 percentage of participants

Primary: Response (CR or PR), Stable Disease (SD), and Progressive Disease (PD) Rates — 6.81; 18.18; 75.00 percentage of participants